Novo Nordisk’s Pipeline Push and Buyback Blitz Face a Reckoning at Q1 Earnings
Novo Nordisk faces a pivotal Q1 earnings test amid share buybacks, pipeline diversification beyond semaglutid, and cautious analyst…
Browsing Tag